Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.

By Jordi Bruix1 , 2, S. Qin, P. Merle, A. Granito, Yi‐Hsiang Huang, G. Bodoky, M. Pracht, O. Yokosuka, O. Rosmorduc, V. Breder and 14 more. The Lancet, 2017

3,215 citations recorded by the source corpus.

Subfields: Hepatology, Pathology and Forensic Medicine, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/71347210f3074827acd4e2d05dbd041b9fefa2df

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Hepatology

1. J. Llovet
2. V. Mazzaferro
3. Alejandro Forner1 , 2
4. Andrew X. Zhu
5. Peter R. Galle
6. R. Finn
7. F. Piscaglia
8. J. Raoul

In Pathology and Forensic Medicine

1. Andrew X. Zhu
2. V. Mazzaferro
3. Alejandro Forner1 , 2
4. J. Llovet

Citations in the corpus

• Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. (2018, background): “Only regorafenib is 102 approved as second-line systemic treatment for patients who failed to respond to sorafenib.(10) Best 103 supportive care or participation in clinical trials is currently recommended by the treatment guidelines in 104 the second-line setting.”